GlaxoWellcome

February 21, 2001

Sec. Surger

6432 '01 FEB 26 AN1 :27

Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

Electronic Filing of Drug Registration and Listing Information: Notice of Pilot Project RE: [Docket No. 00N-1669] Response to FDA Request Regarding Participation in FDA Pilot Project

Dear Mr. Hunter:

On February 5, 2001, Glaxo Wellcome submitted a written request to participate in the FDA Pilot Project involving the electronic filing of drug registration and listing information. Reference is made to your telephone inquiry on February 14, 2001 during which you requested additional information in order to determine if Glaxo Wellcome would be a suitable participant in the Pilot Project.

Listed below is the information requested in the Federal Register Notice dated January 9, 2001 that should allow you to assess Glaxo Wellcome's suitability for participating in the program:

Participant's Name:

Company Name:

Company Address:

Telephone Number of Participant:

Number of Products listed with FDA:

Number of NDA's approved

Brenda Brown, Compliance Specialist, Quality Strategy & Conformance

Glaxo Wellcome Inc.

1011 North Arendell Avenue Zebulon, NC 27597

(919) 269-1563

approximately 600

75 IND 5 Orphan 81 NDA 1 BLA

15

1.178 和ALE 的复数正确的 这些一端的话的复数形式。这些

Number of Establishments Registered with FDA:

Type of Products Processed:

Human and Biological

LET38

DON-1669

Glaxo Wellcome Inc. 1011 N Arendell Avenue PO Box 1217 Zebulon North Carolina 27597

Telephone 919 269 5000 Dockets Management Branch (HFA-305) Food and Drug Administration February 21, 2001 Page Two

Processes Performed:

Manufacturing, Labeling and Distribution

Kinds of Products Processed:

Prescription, Over-the-Counter, Active Pharmaceutical Ingredients

If you need additional information, please contact me at 919-269-1563. I look forward to your response regarding Glaxo Wellcome's participation in the Pilot Program

Sincerely,


A

Buenda D. Been

Brenda R. Brown Compliance Specialist

GlaxoWellcome

Glaxo Wellcome Inc. 1011 N Arendell Avenue PO Box 1217. Zebulon North Carolina 27597



27

Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

20857-0001 million and the second second